Performance evaluation of the Diasorin LIAISON® XL Zika capture IgM CLIA test

Beken, Yolien Van der; Geyter, Deborah De; Esbroeck, Marjan Van

doi:10.1016/j.diagmicrobio.2019.05.004

Cited by 5 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differential diagnosis problems arise with all these viruses. With regard to DENV, the assay evaluated here showed reasonable specificity, since it detects 1/10 false-positive cases, which falls within the range of previously published values (with IIF, two samples tested positive for ZIKV IgM) [16]. On the other hand, we cannot completely exclude the possibility that the sample with a positive IgM result in LIAISON for ZIKV and IgM against CHIKV (25) actually corresponds to a double infection with both viruses, since the sample was obtained when both viruses were simultaneously circulating (2018).…”

Section: Discussionsupporting

confidence: 85%

“…This observation has been made in other studies conducted with ELISA-NS1 [14,15], and suggests that the production of IgM versus NS1 could be delayed, and thereby not detected in the early acute stage (<5 days after the onset of symptoms). However, another study gave positive results with LIAISON in 12/17 samples (70.6%) collected within the first five days of the disease [16]. In this sense, in the present study, 13 samples with suspected ZIKV infection with a negative or undetermined IgM result for IIF and a positive result with LIAISON gave positive results in serum PCR (5 cases) or urine (8 cases), suggesting that these samples were taken at very early stages (samples 1-13, Table 3).…”

Section: Discussionmentioning

confidence: 97%

“…For this reason, it is important to select samples of cases in which problems of differential diagnosis arise. Previously, false-positive reactions have been identified in LIAISON in cases of infection by DENV, Plasmodium falciparum, P. vivax and P. malariae, as well as the Epstein-Barr virus and Cytomegalovirus in patients without a history of traveling to ZIKV-endemic areas [16]. In the present study, we have attempted to assess the specificity using samples of dengue (because of its crossreactivity with flavivirus) and CHIKV (because it is endemic in the same region as ZIKV and DENV), as well as RUBV and MeV (given the current importance of surveillance programs that aim to eliminate these diseases) and HPVB19.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the LIAISON XL Zika Capture IgM II for the Diagnosis of Zika Virus Infections

Pérez‐Olmeda

Sánchez-Seco

Vázquez

et al. 2020

Viruses

View full text Add to dashboard Cite

The aim of this study is to evaluate the performance characteristics of the LIAISON XL Zika Capture IgM II. For this purpose we tested 128 samples obtained from recent infections caused by the Zika (ZIKV; 74 samples), dengue (DENV; 10 samples), chikungunya (CHIK V; 11 samples), rubella (RUBV; 10 samples) and measles (MeV; 10 samples) viruses, as well as human parvovirus B19 (HPVB19; 13 samples). The results of the assay under evaluation are compared with those obtained from an indirect immunofluorescence (IIF) assay, and the discrepancies are resolved by considering other laboratory results (PCR and a plaque-reduction neutralization test). The LIAISON showed excellent sensitivity (100%). The specificity (91.25%) was hampered by some false-positive results in recent dengue virus, chikungunya virus, measles virus and human parvovirus B19 infections. The method evaluated is adequate, but the low specificity makes it necessary to consider the clinical and epidemiological contexts of patients, as well as other laboratory results.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the LIAISON XL Zika Capture IgM II for the Diagnosis of Zika Virus Infections

Pérez‐Olmeda

Sánchez-Seco

Vázquez

et al. 2020

Viruses

View full text Add to dashboard Cite

show abstract

“…Another study that evaluated samples from ZIKV-infected patients with several ELISA kits, demonstrated IgM-E and NS1 sensitivities of 100% and 37%, respectively; however, 83% of the samples were obtained before the first week or more than 30 days PSO, 11 which is not within the IgM detection time frame we observed in this study. Another method that measures IgM-NS1 levels by qualitative capture assay is indirect chemiluminescent immunoassay (CLIA), 22 which also offers higher sensitivity (98.7%) but should be evaluated for the duration that IgM can be detected. Therefore, sensitivities of the IgM-NS1 based ELISA should be reevaluated and assessed according to the time frames PSO to identify the optimal window of detection of this assay and take into account the survival of NS1-IgM antibodies.…”

Section: Discussionmentioning

confidence: 99%

Rapid Decline of Zika Virus IgM Antibodies against the NS1 Protein in Imported Israeli Cases

Lustig

Zuckerman

Koren

et al. 2022

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Zika virus (ZIKV) infection during pregnancy may cause severe fetal abnormalities and therefore it is important to diagnose and distinguish between recent and past Zika infection. Serological diagnosis assays detect antibodies against the envelope protein, that suffer from high cross-reactivity. In addition, reports regarding long IgM persistence prevent its use in diagnosis of recent Zika infection. Following the Zika pandemic, a novel ELISA assay based on detection of antibodies against Zika nonstructural 1 (NS1) protein was developed (NS1-IgM). Here, NS1-IgM antibodies were assessed in Israeli travelers diagnosed with Zika. NS1-IgM and NS1-IgG antibodies from 36 travelers diagnosed with ZIKV infection were detected as early as 5 days after symptom onset. However, while IgG levels were maintained for several months, IgM levels in all samples declined rapidly and by 31 days after symptom onset, no IgM positive samples were detected. Interval-censored survival analysis demonstrated 25%, 50%, and 75% decline in NS1-IgM levels in 29 days (95% CI: 22–34), 34 days (95% CI: 29–44), and 44 days (95% CI: 34–65), respectively. Our results suggest that IgM antibodies against ZIKV NS1 are short lived and can be used as a reliable marker for diagnosis of recent ZIKV infection.

show abstract

Coinfections and antimicrobial treatment in a cohort of falciparum malaria in a non-endemic country: a 10-year experience

Küpper-Tetzel,

Idris,

Kessel

et al. 2023

Infection

View full text Add to dashboard Cite

Introduction Falciparum malaria remains one of the deadliest infectious diseases worldwide. In Germany, it is mainly an imported infection among travellers. Rates of coinfection are often unknown, and a clinical rationale for the beneficial use of calculated antibiotic therapy in patients with malaria and suspected coinfection is lacking. Methods We conducted an analysis of all in-patients treated with falciparum malaria at a German infectious diseases centre in vicinity to one of Europe’s major airports for 2010–2019. Logistic regression and time-to-event analysis were used to evaluate predictors for bacterial coinfection, the use of antibacterial substances, as well as their influence on clinical course. Results In total, 264 patients were included. Of those, 64% received an additional antibacterial therapy (n = 169). Twenty-nine patients (11.0%) were found to have suffered from a relevant bacterial coinfection, while only a small fraction had relevant bacteremia (n = 3, 1.4%). However, patients with severe malaria did not suffer from coinfections more frequently (p = 0.283). CRP levels were not a reliable predictor for a bacterial coinfection (OR 0.99, 95% CI 0.94–1.06, p = 0.850), while another clinical focus of infection was positively associated (OR 3.86, 95% CI 1.45–11.55, p = 0.010). Conclusion Although bacterial coinfections were rare in patients with malaria at our centre, the risk does not seem negligible. These data point rather towards individual risk assessment in respective patients than to general empiric antibiotic use.

show abstract

Performance evaluation of the Diasorin LIAISON® XL Zika capture IgM CLIA test

Cited by 5 publications

References 20 publications

Evaluation of the LIAISON XL Zika Capture IgM II for the Diagnosis of Zika Virus Infections

Evaluation of the LIAISON XL Zika Capture IgM II for the Diagnosis of Zika Virus Infections

Rapid Decline of Zika Virus IgM Antibodies against the NS1 Protein in Imported Israeli Cases

Coinfections and antimicrobial treatment in a cohort of falciparum malaria in a non-endemic country: a 10-year experience

Contact Info

Product

Resources

About